Figure 5. Life years and QALYs gained and cost-effectiveness of lifetime statin therapy in older people: scenario analyses with CVD reductions with statin therapy in people>75 years old informed from effects of statin therapy among participants>75 years old (Scenario 1) or >75 years old without CVD (Scenario 2) from Cholesterol Treatment Trialists’ collaborative meta-analysis. Statin effects up to age 75 as in base-case analysis; statin effect thereafter as per respective scenario analysis. CVD, cardiovascular disease; ICER, Incremental Cost-Effectiveness Ratio with costs and QALYs discounted at 3.5% per year; LDL, low-density lipoprotein; QALY, quality-adjusted life year.